Does Stent Placement for Advanced Colon Cancer Increase the Risk of Perforation During Bevacizumab-Based Therapy?

Clinical Gastroenterology and Hepatology

Volumn 7, Issue 11, 2009, Pages 1174-1176

  Cennamo, Vincenzo ^a   Fuccio, Lorenzo ^a   Mutri, Vita ^b   Minardi, Maria Eugenia ^a   Eusebi, Leonardo Henry ^a   Ceroni, Liza ^a   Laterza, Liboria ^a   Ansaloni, Luca ^b   Pinna, Antonio Daniele ^b   Salfi, Nunzio ^b   Martoni, Andrea Angelo ^b   Bazzoli, Franco ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CAPECITABINE; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN; PANITUMUMAB;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURGERY; CLINICAL ARTICLE; COLON CANCER; COLON PERFORATION; ENDOSCOPY; FEMALE; FOLLOW UP; HUMAN; LUNG METASTASIS; MALE; METASTASIS; PRIMARY TUMOR; RADIOLOGY; SELF EXPANDABLE METALLIC STENT; STENT;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; COLONIC NEOPLASMS; DEOXYCYTIDINE; FLUOROURACIL; HUMANS; INTESTINAL PERFORATION; ORGANOPLATINUM COMPOUNDS; RISK ASSESSMENT; STENTS;

EID: 70350415518     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2009.07.015     Document Type: Article

References (20)

1. Smothers L., Hynan L., Fleming J., et al. Emergency surgery for colon carcinoma. Dis Colon Rectum 46 (2003) 24-30
2. Law W.L., Choi H.K., and Chu K.W. Comparison of stenting with emergency surgery as palliative treatment for obstructing primary left-sided colorectal cancer. Br J Surg 90 (2003) 1429-1433
3. Vandervoort J., and Tham T.C. Colonic stents for malignant obstruction-not a bridge too far?. Gastrointest Endosc 64 (2006) 921-924
4. Repici A., De Caro G., Luigiano C., et al. WallFlex colonic stent placement for management of malignant colonic obstruction: a prospective study at two centers. Gastrointest Endosc 67 (2008) 77-84
5. Fregonese D., Naspetti R., Ferrer S., et al. Ultraflex precision colonic stent placement as a bridge to surgery in patients with malignant colon obstruction. Gastrointest Endosc 67 (2008) 68-73
6. Baron T.H. Expandable metal stents for the treatment of cancerous obstruction of the gastrointestinal tract. N Engl J Med 344 (2001) 1681-1687
7. Lopes C.V., Pesenti C., Bories E., et al. Self-expandable metallic stents for palliative treatment of digestive cancer. J Clin Gastroenterol 42 (2008) 991-996
8. Baron T.H., Rey J.F., and Spinelli P. Expandable metal stent placement for malignant colorectal obstruction. Endoscopy 34 (2002) 823-830
9. Badgwell B.D., Camp E.R., Feig B., et al. Management of bevacizumab-associated bowel perforation: a case series and review of the literature. Ann Oncol 19 (2008) 577-582
10. Kabbinavar F.F., Hurwitz H.I., Yi J., et al. Addition of bevacizumab to fluorouracil-based first-line treatment of metastatic colorectal cancer: pooled analysis of cohorts of older patients from two randomized clinical trials. J Clin Oncol 27 (2009) 199-205
11. Hurwitz H., Fehrenbacher L., Novotny W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350 (2004) 2335-2342
12. Chen H.X., Mooney M., Boron M., et al. Phase II multicenter trial of bevacizumab plus fluorouracil and leucovorin in patients with advanced refractory colorectal cancer: an NCI Treatment Referral Center Trial TRC-0301. J Clin Oncol 24 (2006) 3354-3360
13. Saltz L.B., Clarke S., Diaz-Rubio E., et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 26 (2008) 2013-2019
14. Genentech. Bevacizumab prescribing information. http://www.gene.com/gene/products/information/oncology/avastin/ Accessed October 27, 2008
15. Cennamo V., Fuccio L., Laterza L., et al. Side-viewing endoscope for colonic self-expandable metal stenting in patients with malignant colonic obstruction. Eur J Gastroenterol Hepatol 21 (2009) 585-586
16. Dworak O., Keilholz L., and Hoffmann A. Pathological features of rectal cancer after preoperative radiochemotherapy. Int J Colorectal Dis 12 (1997) 19-23
17. Han E.S., and Monk B.J. What is the risk of bowel perforation associated with bevacizumab therapy in ovarian cancer?. Gynecol Oncol 105 (2007) 3-6
18. Heinzerling J.H., and Huerta S. Bowel perforation from bevacizumab for the treatment of metastatic colon cancer: incidence, etiology, and management. Curr Surg 63 (2006) 334-337
19. Saif M.W., Elfiky A., and Salem R.R. Gastrointestinal perforation due to bevacizumab in colorectal cancer. Ann Surg Oncol 14 (2007) 1860-1869
20. Hapani S., Chu D., and Wu S. Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis. Lancet Oncol 10 (2009) 559-568